The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: ePRO for the Timely Detection of Side Effects in Cancer Patients Undergoing CAR T Immunotherapy
Official Title: ePRO for the Timely Detection of Side Effects in Cancer Patients Undergoing CAR T Immunotherapy: Feasibility Study (CARTePRO)
Study ID: NCT05354973
Brief Summary: This study is designed as a feasibility study implementing electronic Patient Reported Outcomes (ePRO) in CAR T treatment for hematological malignancies, in order to describe AE reporting. ePRO assessments will be explored for their feasibility to engage in monitoring and management of CAR T-related toxicities as well as using these digital ePRO tools may improve both, its safety and accessibility.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Klinik für Hämatologie und Onkologie, Zürich, , Switzerland
Name: Panagiotis Samaras, PD.Dr.med
Affiliation: Klinik für Hämatologie und Onkologie
Role: PRINCIPAL_INVESTIGATOR